{"url_path":"/sec/entx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-002458-index.html","accession_number":"0001178913-26-002458","cik":"0001638097","ticker":"ENTX","issuer_name":"Entera Bio Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1638097/0001178913-26-002458-index.html","primary_entity_key":"0001638097","primary_entity_name":"Entera Bio Ltd."},"word_count":2110,"has_tables":true,"body_markdown":"Entera Bio Ltd. - 1638097 - 2026\n\nRepresents an amount less than one thousand U.S. dollars.\n1Other development expenses include materials and productions and others.\nOther segment expenses mainly related to general and administrative expenses, including payroll and related expenses, share-based compensation, legal and audit fees and others.\n0001638097falseQ1--12-3100-0000000\n\n0001638097\n2026-03-31\n\n0001638097\n2026-01-01\n2026-03-31\n\n0001638097\n2025-01-01\n2025-03-31\n\n0001638097\n2024-12-31\n\n0001638097\n2025-12-31\n\n0001638097\n2025-03-31\n\n0001638097us-gaap:RetainedEarningsMember\n2025-12-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2025-12-31\n\n0001638097us-gaap:CommonStockMember\n2025-12-31\n\n0001638097us-gaap:RetainedEarningsMember\n2026-01-01\n2026-03-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2026-01-01\n2026-03-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2026-01-01\n2026-03-31\n\n0001638097us-gaap:CommonStockMember\n2026-01-01\n2026-03-31\n\n0001638097us-gaap:RetainedEarningsMember\n2026-03-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2026-03-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2026-03-31\n\n0001638097us-gaap:CommonStockMember\n2026-03-31\n\n0001638097us-gaap:RetainedEarningsMember\n2025-01-01\n2025-03-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2025-01-01\n2025-03-31\n\n0001638097us-gaap:CommonStockMember\n2025-01-01\n2025-03-31\n\n0001638097us-gaap:RetainedEarningsMember\n2024-12-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2024-12-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2024-12-31\n\n0001638097us-gaap:CommonStockMember\n2024-12-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2025-01-01\n2025-03-31\n\n0001638097us-gaap:RetainedEarningsMember\n2025-03-31\n\n0001638097us-gaap:AccumulatedOtherComprehensiveIncomeMember\n2025-03-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2025-03-31\n\n0001638097us-gaap:CommonStockMember\n2025-03-31\n\n0001638097us-gaap:AdditionalPaidInCapitalMember\n2025-12-31\n\n0001638097entx:OpkoBiologicsLtdMember\n2025-03-11\n2025-03-16\n\n0001638097entx:OpkoBiologicsLtdMember\n2026-01-01\n2026-03-31\n\n0001638097entx:FiveNonExecutiveMembersMember\n2026-01-01\n2026-01-01\n\n0001638097entx:FormerNonExecutiveBoardMember\n2026-02-01\n2026-02-28\n\n0001638097us-gaap:SubsequentEventMemberentx:BvfPartnersLpMember\n2026-04-01\n2026-04-01\n\n0001638097us-gaap:SubsequentEventMemberentx:BvfPartnersLpMember\n2026-04-01\n\n0001638097us-gaap:CommonStockMemberus-gaap:SubsequentEventMemberentx:BvfPartnersLpMember\n2026-04-02\n2026-04-02\n\n0001638097us-gaap:WarrantMemberus-gaap:SubsequentEventMemberentx:BvfPartnersLpMember\n2026-04-02\n2026-04-02\n\n0001638097entx:OrdinaryShareWarrantsMemberus-gaap:SubsequentEventMemberentx:BvfPartnersLpMember\n2026-04-02\n2026-04-02\n\n0001638097entx:FormerNonExecutiveBoardMemberus-gaap:SubsequentEventMember\n2026-04-30\n2026-04-30\n\n0001638097entx:EmployeesConsultantsAndExecutiveOfficerMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097srt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097entx:EmployeesConsultantsAndExecutiveOfficerMemberus-gaap:SubsequentEventMember\n2026-05-07\n\n0001638097srt:ChiefExecutiveOfficerMemberus-gaap:SubsequentEventMember\n2026-05-07\n\n0001638097us-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097entx:BoardMembersMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097entx:CertainBoardMembersMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember\n2026-05-01\n2026-05-07\n\n0001638097entx:CertainBoardMembersMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember\n2026-05-01\n2026-05-07\n\n0001638097entx:BoardMembersMemberus-gaap:SubsequentEventMember\n2026-05-07\n\n0001638097entx:CertainBoardMembersMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember\n2026-05-07\n\n0001638097entx:CertainBoardMembersMemberus-gaap:SubsequentEventMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember\n2026-05-07\n\n0001638097us-gaap:RestrictedStockUnitsRSUMemberentx:ExecutiveOfficersMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097us-gaap:RestrictedStockUnitsRSUMemberentx:ShareholdersMemberus-gaap:SubsequentEventMember\n2026-05-01\n2026-05-07\n\n0001638097\n2026-05-04\niso4217:ILSxbrli:shares\nxbrli:pure\nentx:Segment\niso4217:USD\niso4217:USDxbrli:shares\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n (Mark One)\n\n☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the transition period from                       to                     **\n\n \n\n**Commission File Number: 001-38556**\n\n \n\n**ENTERA BIO LTD.**\n\n**(Exact name of Registrant as specified in its charter)**\n\n \n\n**Israel**\n \n**Not applicable**\n\n**(State or other jurisdiction of**\n \n**(I.R.S. Employer**\n\n**incorporation or organization)**\n \n**Identification No.)**\n\n \n \n \n\n**Kiryat Hadassah**\n\n**Minrav Building – Fifth Floor**\n\n \n \n\n**Jerusalem, Israel**\n \n**9112002**\n\n**(Address of principal executive offices)**\n \n**(Zip Code)**\n\n** **\n\n**972-2-532-7151**\n\n**(Registrant’s telephone number, including area code)**\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n \n**Trading Symbol**\n \n**Name of Each Exchange on Which Registered**\n\n**Ordinary Shares, par value**\n\n**NIS 0.0000769 per share**\n\n \n**ENTX**\n \n**Nasdaq Capital Market**\n\n**  ** \n\nIndicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\n\n \n\nYes ☒   No  ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\n\n \n\nYes  ☒   No  ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n☐\nAccelerated filer\n☐\n\nNon-Accelerated filer\n☒\nSmaller reporting company\n☒\n\n \n \nEmerging growth company\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)\n\n \n\nYes ☐  No ☒\n\n         \n\nAs of May 4, 2026, the registrant had 49,225,321 ordinary shares, par value NIS 0.0000769 per share (“Ordinary Shares”) outstanding.   \n\n \n\n \n\n \n\n**Table of Contents**\n\n \n\n  **Page**\n\n**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**1\n\n**PART I – FINANCIAL INFORMATION**3\n\n   \n\n[Item 1.](#i1)[Financial Statements](#i1)3\n\n [Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (unaudited)](#SHEETS)4\n\n [Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 2025 (unaudited)](#OPERATIONS)5\n\n [Condensed Consolidated Statement of Changes in Shareholders’ Equity for the three months ended March 31, 2026 and 2025 (unaudited)](#EQUITY)6\n\n [Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (unaudited)](#FLOWS)7\n\n [Notes to Condensed Consolidated Financial Statements (unaudited)](#NOTES)8\n\n[Item 2.](#i2)[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2)15\n\n[Item 3.](#i3)[Quantitative and Qualitative Disclosures About Market Risk](#i3)27\n\n[Item 4.](#i4)[Controls and Procedures](#i4)27\n\n   \n\n**PART II – OTHER INFORMATION**28\n\n \n\n[Item 1.](#p2i1)[Legal Proceedings](#p2i1)28\n\n[Item 1A.](#p2i1a)[Risk Factors](#p2i1a)28\n\n[Item 2.](#p2i2)[Unregistered Sales of Equity Securities and Use of Proceeds](#p2i2)29\n\n[Item 3.](#p2i3)[Defaults Upon Senior Securities](#p2i3)29\n\n[Item 4.](#p2i4)[Mine Safety Disclosures](#p2i4)29\n\n[Item 5.](#p2i5)[Other Information](#p2i5)29\n\n[Item 6.](#p2i6)[Exhibits](#p2i6)30\n\n \n\n**SIGNATURES**31\n\n \n\n \n\n \n\n \n\n**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (“PSLRA”), Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Various statements in this Quarterly Report are “forward-looking statements” within the meaning of the PSLRA and other U.S. Federal securities laws. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not be different, and historic results referred to in this Quarterly Report may be interpreted differently in light of additional research and clinical and preclinical trial results. Forward-looking statements include all statements that are not historical facts. We have based these forward-looking statements largely on our management’s current expectations and future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words including, but not limited to, “anticipate,” “believe,” “contemplates,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “likely,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will,” “would,” “seek,” “should,” “target,” or the negative of these terms and similar expressions or words, identify forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements. These factors include those described in “Part II, Item 1A-Risk Factors” of this Quarterly Report and in “Part I, Item 1A-Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (the “2025 Annual Report”). Meaningful factors that could cause actual results to differ from those expressed in forward-looking statements include, but are not limited to:\n\n \n\n•Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates; \n\n \n\n•The regulatory approval processes of the U.S. Food and Drug Administration (“FDA”) and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed; \n\n \n\n•Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all;\n\n \n\n•Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials; \n\n \n\n•The scope, progress and costs of developing our product candidates such as EB613 for osteoporosis and EB612 for hypoparathyroidism or other oral peptides for the treatment of obesity, metabolic disorders (EB618) and gastrointestinal rare diseases may alter over time based on various factors such as regulatory requirements, collaboration agreements, the competitive environment and new data from pre-clinical and clinical studies;\n\n \n\n•The accuracy of our estimates regarding expenses, capital requirements, the sufficiency of our cash resources and the need for additional financing; \n\n \n\n•Our ability to continue as a going concern absent access to sources of liquidity;\n\n \n\n•Our ability to raise additional funds or consummate strategic partnerships to offset additional required capital to pursue our business objectives, which may not be available on acceptable terms or at all. A failure to obtain this additional capital when needed, or failure to consummate strategic partnerships, could delay, limit or reduce our product development, and other operations;\n\n \n\n1 \n\n \n\n•Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success; \n\n \n\n•The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and third-party payors establish adequate coverage and reimbursement levels and pricing policies; \n\n \n\n•Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue; \n\n \n\n•If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected; \n\n \n\n•Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain;\n\n \n\n•Our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; \n\n \n\n•Our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plan; \n\n \n\n•Our ability to use and expand our N-Tab® platform to additional product candidates;\n\n \n\n•Our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward;\n\n \n\n•Our competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome and other rare gastrointestinal disorders, obesity, metabolic conditions and other disease categories we pursue;\n\n \n\n•Our ability to establish and maintain development and commercialization collaborations;\n\n \n\n•Our ability to manufacture and supply enough material to support our clinical trials and any potential future commercial requirements;\n\n \n\n•The size of any market we may target and the adoption of our product candidates, if approved, by physicians and patients;\n\n \n\n•Our ability to obtain, maintain and protect our intellectual property and operate our business without infringing, misappropriating, or otherwise violating any intellectual property rights of others;\n\n \n\n•Our ability to retain key personnel and recruit additional qualified personnel;\n\n \n\n•Our ability to comply with laws and regulations that currently apply or become applicable to our business;\n\n \n\n•Our ability to manage growth; and\n\n \n\n•The Israel-Hamas conflict, that has been ongoing since October 2023, including involvement from Hezbollah, Iran and its proxies in the Middle East, such as the Houthis in Yemen and militias in Iraq and Syria, as well as the hostilities between the United States, Israel and Iran, and their impact on our operations and workforce, remains unknown.\n\n \n\nAll forward-looking statements contained in this Quarterly Report are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely heavily on the forward-looking statements we make. Except as required by applicable law, we are under no duty, and expressly disclaim any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult all further disclosures we make in each annual, quarterly or current report that we file with the Securities and Exchange Commission (“SEC”).\n\n \n\nWe encourage you to read Part II, Item 1A of this Quarterly Report and Part I, Item 1A of our 2025 Annual Report, each entitled “Risk Factors,” and Part I, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operation—Liquidity and Capital Resources” of this Quarterly Report for additional discussion of the risks and uncertainties associated with our business. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.\n\n \n\n2 \n\n \n\n**PART I.**"}